Exelixis

Study estimates HCC incidence in SLD patients, finding higher rates in males, older individuals, those with cirrhosis, DM, CKD, CVD, and non-liver cancer. Incidence rises with age, male sex, cirrhosis, and DM, peaking at 19.06/1,000 PY in males >70 with cirrhosis and DM. Lowest risk is in noncirrhotic, nondiabetic patients <40. Results suggest tailored surveillance strategies based on multiple risk factors.

Newly described lymph node-like structures in liver tumors after immunotherapy may be crucial for treating hepatocellular carcinoma, potentially increasing the likelihood of curing the cancer, according to a study by Johns Hopkins researchers.

The article content is not provided for summarization.

Merck and Exelixis plan to collaborate on clinical trials combining Exelixis’ zanzalintinib with Merck’s Keytruda for HNSCC and Welireg for RCC, aiming to improve outcomes in these cancers.

Exelixis wins patent litigation against MSN Laboratories; U.S. District Court upholds validity of three cabozantinib patents, delaying MSN's generic launch until January 15, 2030.

Exelixis and Merck announce clinical collaboration to evaluate zanzalintinib with KEYTRUDA in HNSCC and with WELIREG in RCC, aiming to address unmet needs. Exelixis retains global rights to zanzalintinib, while Merck supplies KEYTRUDA and funds part of the RCC trials.

E. Heath reports advisory/consulting, steering committee, honoraria/paid travel, speaker’s bureau, and research support from various companies. J.R. Ribeiro, K. Poorman, and J. Xiu report personal fees and other support from Caris Life Sciences. H. Mamdani reports other support and grants from Daiichi Sankyo, AstraZeneca, and Genentech. A.F. Shields reports personal fees from Caris Life Sciences. G.L. Lopes reports stock ownership, honoraria, consulting, research funding, travel, and other relationships with multiple companies. S.A. Kareff reports personal fees and travel grants from various organizations. M. Radovich and G.W. Sledge report other support from Caris Life Sciences. G.A. Vidal reports relationships with Guardant360, Gilead, BillionToOne, Genentech/Roche, GSK, and AstraZeneca. J.L. Marshall reports personal fees from Caris. No other disclosures were reported by the other authors.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

FDA approves selpercatinib (Retevmo) for advanced or metastatic medullary thyroid cancer (MTC) with RET mutation in adults and pediatric patients aged 2 years and older. The approval is based on the LIBRETTO-531 trial, showing selpercatinib's efficacy with progression-free survival (PFS) not reached compared to 16.8 months in the control arm. Selpercatinib's dosing varies by age and body surface area, with reduced severe side effects reported compared to other treatments.